SG11202102904TA - Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa - Google Patents
Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativaInfo
- Publication number
- SG11202102904TA SG11202102904TA SG11202102904TA SG11202102904TA SG11202102904TA SG 11202102904T A SG11202102904T A SG 11202102904TA SG 11202102904T A SG11202102904T A SG 11202102904TA SG 11202102904T A SG11202102904T A SG 11202102904TA SG 11202102904T A SG11202102904T A SG 11202102904TA
- Authority
- SG
- Singapore
- Prior art keywords
- elr
- pan
- treatment
- cxc chemokine
- hidradenitis suppurativa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748838P | 2018-10-22 | 2018-10-22 | |
| US201962791061P | 2019-01-11 | 2019-01-11 | |
| PCT/US2019/056250 WO2020086327A1 (en) | 2018-10-22 | 2019-10-15 | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102904TA true SG11202102904TA (en) | 2021-05-28 |
Family
ID=68425364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102904TA SG11202102904TA (en) | 2018-10-22 | 2019-10-15 | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12037387B2 (ko) |
| EP (1) | EP3870288A1 (ko) |
| JP (2) | JP7171913B2 (ko) |
| KR (2) | KR20240014601A (ko) |
| CN (1) | CN112912140B (ko) |
| AU (1) | AU2019364239B2 (ko) |
| BR (2) | BR112021004900A2 (ko) |
| CA (1) | CA3117142A1 (ko) |
| IL (1) | IL282307A (ko) |
| MA (1) | MA53976A (ko) |
| MX (1) | MX2021004363A (ko) |
| MY (1) | MY197879A (ko) |
| SG (1) | SG11202102904TA (ko) |
| TW (1) | TWI737000B (ko) |
| UA (1) | UA128649C2 (ko) |
| WO (1) | WO2020086327A1 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206457A (zh) * | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012014080A (es) * | 2010-06-03 | 2013-05-01 | Abbvie Biotechnology Ltd | Usos y composiciones para el tratamiento de hidradenitis superativa (hs). |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| US9290570B2 (en) * | 2013-03-15 | 2016-03-22 | Eli Lilly And Company | Pan-ELR+ CXC Chemokine Antibodies |
| KR101418306B1 (ko) | 2013-03-19 | 2014-07-15 | 김대운 | 바지의 흘러내림 방지용 버팀기둥 |
| WO2015197098A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2016098071A1 (en) * | 2014-12-18 | 2016-06-23 | Csir | Immunomodulation by controlling elr+ proinflammatory chemokine levels with the long non-coding rna umlilo |
| CA3053231A1 (en) * | 2017-02-16 | 2018-08-23 | Xbiotech Inc. | Treatment of hidradenitis suppurativa |
-
2019
- 2019-10-08 TW TW108136327A patent/TWI737000B/zh active
- 2019-10-15 MA MA053976A patent/MA53976A/fr unknown
- 2019-10-15 US US17/284,611 patent/US12037387B2/en active Active
- 2019-10-15 MX MX2021004363A patent/MX2021004363A/es unknown
- 2019-10-15 KR KR1020247002081A patent/KR20240014601A/ko not_active Application Discontinuation
- 2019-10-15 CA CA3117142A patent/CA3117142A1/en active Pending
- 2019-10-15 EP EP19797521.2A patent/EP3870288A1/en active Pending
- 2019-10-15 MY MYPI2021002149A patent/MY197879A/en unknown
- 2019-10-15 BR BR112021004900-2A patent/BR112021004900A2/pt unknown
- 2019-10-15 SG SG11202102904TA patent/SG11202102904TA/en unknown
- 2019-10-15 UA UAA202101781A patent/UA128649C2/uk unknown
- 2019-10-15 BR BR122023023399-9A patent/BR122023023399A2/pt unknown
- 2019-10-15 AU AU2019364239A patent/AU2019364239B2/en active Active
- 2019-10-15 CN CN201980069911.0A patent/CN112912140B/zh active Active
- 2019-10-15 KR KR1020217011560A patent/KR102628314B1/ko active Application Filing
- 2019-10-15 WO PCT/US2019/056250 patent/WO2020086327A1/en active Application Filing
- 2019-10-15 JP JP2021521030A patent/JP7171913B2/ja active Active
-
2021
- 2021-04-13 IL IL282307A patent/IL282307A/en unknown
-
2022
- 2022-11-02 JP JP2022176098A patent/JP7410256B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102628314B1 (ko) | 2024-01-25 |
| CN112912140A (zh) | 2021-06-04 |
| TWI737000B (zh) | 2021-08-21 |
| US20210340244A1 (en) | 2021-11-04 |
| CN112912140B (zh) | 2024-08-20 |
| WO2020086327A1 (en) | 2020-04-30 |
| JP2023011819A (ja) | 2023-01-24 |
| UA128649C2 (uk) | 2024-09-18 |
| JP7410256B2 (ja) | 2024-01-09 |
| EP3870288A1 (en) | 2021-09-01 |
| MX2021004363A (es) | 2021-05-31 |
| US12037387B2 (en) | 2024-07-16 |
| BR112021004900A2 (pt) | 2021-06-01 |
| KR20240014601A (ko) | 2024-02-01 |
| JP7171913B2 (ja) | 2022-11-15 |
| TW202028233A (zh) | 2020-08-01 |
| CA3117142A1 (en) | 2020-04-30 |
| KR20210060582A (ko) | 2021-05-26 |
| AU2019364239A1 (en) | 2021-04-22 |
| MA53976A (fr) | 2022-01-26 |
| IL282307A (en) | 2021-05-31 |
| JP2022512721A (ja) | 2022-02-07 |
| BR122023023399A2 (pt) | 2024-02-20 |
| AU2019364239B2 (en) | 2023-02-02 |
| MY197879A (en) | 2023-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2599290B (en) | Minimizing transducer settling time | |
| IL277858A (en) | Antibodies specific for human nectin-4 | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| IL268125A (en) | Pridopidine for the treatment of fragile x syndrome | |
| EP3893883A4 (en) | METHODS FOR THE TREATMENT OF DEPRESSION | |
| IL268569A (en) | Treatment of hidradenitis suppurativa | |
| GB2593352B (en) | Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone) | |
| IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
| EP3837286A4 (en) | ANTIBODIES TO HUMAN ZNT8 | |
| LT3765440T (lt) | N-alkil-nitratoetilnitraminų gamybos būdas | |
| IL274363B1 (en) | Use of a specific anti-protein siRNA for the treatment of hemophilia | |
| IL284338A (en) | Antibodies against CD40 for use in the treatment of hidradenitis suppurativa | |
| IL282307A (en) | PAN–ELR+ CXC antibodies as a cytokine for the treatment of hidradenitis suppurativa | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| EP3877361C0 (en) | PROCESS FOR PREPARING ARYLSULFONYLPROPENENITRILE | |
| EP3867272A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES | |
| GB2587996B (en) | Structural body | |
| EP3735423A4 (en) | NEO-201 MONOCLONAL ANTIBODY FOR TREATMENT OF HUMAN CARCINOMA | |
| GB201808575D0 (en) | Methods for the treatment of psoriatic arthrits | |
| IL284307A (en) | Methods for treating hidradenitis suppurativa using LTA4H | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| SG11202101102UA (en) | Afucosylated antibodies and manufacture thereof | |
| GB2572385B (en) | Process for the preparation of glycidol | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów |